We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
+24.5%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$2.32B
AUM Growth
+$320M
Cap. Flow
-$21M
Cap. Flow %
-0.9%
Top 10 Hldgs %
48.35%
Holding
91
New
25
Increased
18
Reduced
19
Closed
23

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$95.5M
2
VERA icon
Vera Therapeutics
VERA
+$82M
3
CLDX icon
Celldex Therapeutics
CLDX
+$53.3M
4
ABVX
Abivax
ABVX
+$39.5M
5
BLTE
Belite Bio
BLTE
+$38.3M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$190M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$84.4M
3
TERN
Terns Pharmaceuticals
TERN
+$79.1M
4
CYTK icon
Cytokinetics
CYTK
+$57.7M
5
UTHR icon
United Therapeutics
UTHR
+$47.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ERAS icon
1
Erasca
ERAS
$5.69B
$223M 9.58%
12,150,000
+1,000,000
+9% +$14.3M
ABVX
2
Abivax
ABVX
$9.95B
$136M 5.87%
1,024,000
+349,000
+52% +$39.5M
RVMD icon
3
Revolution Medicines
RVMD
$45.2B
$131M 5.64%
700,000
-1,300,000
-65% -$190M
IDYA icon
4
IDEAYA Biosciences
IDYA
$3.86B
$112M 4.81%
3,000,000
-450,000
-13% -$13.8M
BNTX icon
5
BioNTech
BNTX
$25.8B
$94.4M 4.07%
+1,015,000
New +$95.5M
VERA icon
6
Vera Therapeutics
VERA
$2.52B
$94.4M 4.06%
+2,200,000
New +$82M
TNGX icon
7
Tango Therapeutics
TNGX
$3.84B
$89.1M 3.84%
2,850,000
-150,000
-5% -$3.71M
PRAX icon
8
Praxis Precision Medicines
PRAX
$9.92B
$87M 3.75%
260,000
-25,000
-9% -$7.91M
CLDX icon
9
Celldex Therapeutics
CLDX
$3.09B
$78.1M 3.36%
2,100,000
+1,650,000
+367% +$53.3M
DNTH icon
10
Dianthus Therapeutics
DNTH
$6.03B
$78M 3.36%
800,000
+400,000
+100% +$34.9M
CGON icon
11
CG Oncology
CGON
$6.59B
$71M 3.06%
1,000,000
+425,000
+74% +$27.8M
IRON icon
12
Disc Medicine
IRON
$3.05B
$64M 2.76%
875,000
+315,000
+56% +$21.6M
MAZE
13
Maze Therapeutics
MAZE
$1.44B
$57.7M 2.49%
1,935,000
+700,000
+57% +$18.3M
DYN icon
14
Dyne Therapeutics
DYN
$4.66B
$56.6M 2.44%
2,550,000
+1,150,000
+82% +$21.4M
MLTX icon
15
MoonLake Immunotherapeutics
MLTX
$1.29B
$52.1M 2.24%
2,675,000
+1,175,000
+78% +$21.3M
OCUL icon
16
Ocular Therapeutix
OCUL
$2.34B
$52M 2.24%
5,300,000
+1,450,000
+38% +$13.1M
DSGN icon
17
Design Therapeutics
DSGN
$941M
$43.4M 1.87%
3,000,000
+1,050,000
+54% +$13.1M
OLMA icon
18
Olema Pharmaceuticals
OLMA
$939M
$40.1M 1.73%
3,208,875
– –
BLTE
19
Belite Bio
BLTE
$6.89B
$38.5M 1.66%
+250,000
New +$38.3M
ACHV icon
20
Achieve Life Sciences
ACHV
$855M
$35.4M 1.53%
+5,425,000
New +$25.9M
TRVI icon
21
Trevi Therapeutics
TRVI
$2.43B
$35.1M 1.51%
1,880,000
-520,000
-22% -$7.56M
COGT icon
22
Cogent Biosciences
COGT
$6.06B
$34.8M 1.5%
+900,000
New +$31.5M
AVBP icon
23
ArriVent BioPharma
AVBP
$1.53B
$34.7M 1.5%
1,000,000
+650,000
+186% +$19.2M
CBIO
24
Crescent Biopharma
CBIO
$758M
$34.2M 1.47%
1,900,000
+1,417,500
+294% +$27.7M
CMPS
25
Compass Pathways
CMPS
$1.84B
$31.8M 1.37%
+2,250,000
New +$22.8M
1
2 3 4

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q2 2026 Portfolio in Review

As of Q2 2026, Logos Global Management held 91 positions worth $2.32B, up 16% from $2B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Logos Global Management's Q2 2026 filing shows 25 new, 18 increased, 19 reduced and 23 closed positions. Its largest new stake was BioNTech: 1,015,000 shares worth $94.4M. The largest sale was Revolution Medicines, an estimated $190M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier, followed by Financials.

  • Logos Global Management's largest Q2 2026 buy was BioNTech: 1,015,000 shares worth $94.4M.
  • Logos Global Management added most to Celldex Therapeutics in Q2 2026, an estimated $53.3M increase.
  • Logos Global Management's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $190M.
  • Logos Global Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $84.4M.
  • Logos Global Management's ten largest holdings make up 48% of its $2.32B portfolio in Q2 2026.
  • Logos Global Management opened 25 new positions and closed 23 in Q2 2026.
  • Logos Global Management's portfolio value rose 16% quarter-over-quarter to $2.32B.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.